english.prescrire.org > Spotlight > 100 most recent > In the May issue of Prescrire International - The year in review: New drugs and new indications in 2016

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the May issue of Prescrire International - The year in review: New drugs and new indications in 2016

FREE DOWNLOAD Each month, Prescrire publishes its independent, methodical, systematic reviews, analysing new drugs, new indications for drugs already on the market, and existing drugs authorised in a new pharmaceutical form or at a new dose strength. In 2016, Prescrire’s Editorial Staff analysed the clinical evaluation data for 92 drugs.
Full text available for free download.

Summary

  • Little therapeutic progress was made in 2016, yet many medicines with no clinical value, uncertain efficacy or an unfavourable harm-benefit balance were authorised.
     
  • This is due at least in part to the current system that drives pharmaceutical research and development.
     
  • The primary focus is neither on patients’ needs nor on delivering genuine therapeutic advances at affordable prices.

Full text available for free download.

 ©Prescrire 1 May 2017

"New products and new indications in 2016: a system that favours imitation over the pursuit of real progress" Prescrire Int 2017; 26 (182): 136-139. (Pdf, free)
Download the full review
Pdf, free

See also:

Prescrire's ratings: new
products and indications
over the last 10 years
(May 2017)
Free